AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On May 9, 2017, the Company posted to its website a set of
presentation materials in conjunction with its earnings call and
webcast to assist participants with understanding the Companys
financial results for the quarter ended March 31, 2017. A copy of
this presentation is attached hereto as Exhibit 99.1.
presentation materials in conjunction with its earnings call and
webcast to assist participants with understanding the Companys
financial results for the quarter ended March 31, 2017. A copy of
this presentation is attached hereto as Exhibit 99.1.
The information responsive to this Item 7.01 of this Form 8-K,
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Exchange Act or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the
Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
99.1
|
Presentation materials dated May 9, 2017*
|
|
* This information shall be deemed to be “furnished” and not
filed herewith.
filed herewith.
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Recent Trading Information
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) closed its last trading session up +0.10 at 9.98 with 551,911 shares trading hands.
